Stocks
Amgen Stock Dips After-Hours Amid Research Progress
Amgen's stock price closed at EUR 372.85 after-hours on September 30, 2026, down 0.08 percent compared to its prior close of EUR 373.15.
This development occurred at Lang & Schwarz, a Frankfurt-based trading platform, at around 6:48 p.m. CEST.
It's worth noting that Amgen has been making progress in its research and development efforts, particularly with its Phase 3 OASIZ 301 study on dazodalibep for treating Sjögren's disease.
The company announced on September 22, 2026, that the trial met its primary endpoint, showing statistically significant and clinically meaningful improvement at Week 48, as measured by the EULAR Sjögren's Syndrome Disease Activity Index.